Researchers map "genomic landscape" of childhood adrenocortical tumors for the first time

MEMPHIS, Tenn., March 6, 2015 /PRNewswire-USNewswire/ -- In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the "genomic landscape" of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant genetic and chromosomal changes that drive the cancer, but the sequence of those changes that trigger it.

The study was led by Raul Ribeiro, M.D., Jinghui Zhang, Ph.D., and Gerard Zambetti, Ph.D., all members respectively, of the Departments of Oncology, Computational Biology and Pathology at St. Jude Children's Research Hospital. The researchers published their findings online today in the journal Nature Communications. First authors of the paper were Emilia Pinto, Ph.D., St. Jude Pathology, and Xiang Chen, Ph.D., St. Jude Computational Biology.

Understanding the genetic machinery that drives these tumors is critical because of the difficulty in reliably classifying which childhood adrenocortical tumors would prove to be malignant. Currently, only about half of children with these tumors remain cancer-free after treatment, and those with advanced cancers have very poor overall survival.

"We haven't had any good markers to establish a prognosis," Ribeiro said. "The only characteristic that was somewhat consistent was tumor size, with larger tumors having a worse outcome than smaller ones. But even then, we would have cases where patients with large tumors would have good prognoses, and those with smaller tumors would do poorly." 

Zambetti said scientists in the field had identified only a few genetic markers that seemed to predispose children to these tumors.  

"Pediatric adrenocortical tumors had never been analyzed on a genomic scale before," Zambetti said. When the researchers sequenced the genomes of the tumor and blood samples from the 37 patients with early-to late-stage disease, they pinpointed key mutations involved in these tumors as well as their timing in cancer development.

One key genetic mutation was detected in the gene called TP53, which resides on chromosome 17p. TP53 acts as a "brake" on cell division under stress conditions, so its inactivation by mutation would unleash the uncontrolled proliferation of cancer cells.

A second key molecular event uncovered by the study occurs on chromosome 11. This chromosome harbors a gene called IGF2, which expresses a protein from the paternal allele that promotes cell growth. Analysis of genomic DNA from the patients and their parents by Pinto revealed the selective loss of the maternal chromosome 11 and duplication of paternal chromosome 11 in the pediatric adrenocortical tumors, leading to the continuous high expression of the IGF2 protein and abnormal cell growth.

"With the chromosome 11 abnormality plus the TP53 mutation, you've lost the brakes and stepped on the accelerator at the same time," Zambetti said.

The genomic analysis also yielded the timing of these molecular events. Bioinformaticists Chen and Zhang determined that the chromosomal 17 and 11 abnormalities occur early in tumor development, indicating a fundamental role for these genetic alterations in triggering tumor development.

According to Ribeiro, data on the cancers' genetic landscape offer a highly promising research pathway to understanding the biology and evolution of childhood adrenocortical tumors. "Our focus now will be to determine whether the genomic abnormalities we have distinguished have clinical value in determining the prognosis for these tumors," he said.

In particular, the research team wants to confirm in a larger group of patients that a specific combination of mutations in genes called ATRX and TP53 do lead to more aggressive tumors with poorer prognosis.

The researchers said their studies may also lead to insights into other childhood cancers that also show deregulation of chromosome 11 and over-activity of IGF2, such as rhabdomyosarcoma, Wilms tumor and hepatoblastoma.

The findings also offer considerable promise for improving the treatment of childhood adrenocortical tumors. The study reveals tumor cases with more chaotic molecular changes that will require a different treatment approach. "A key to improving treatment will be using the new genomic knowledge to develop mouse models that would enable more systematic testing, not only of existing therapies, but new ones," Zambetti said.

The other authors are John Easton, David Finkelstein, Zhifa Liu, Stanley Pounds, Kristy Boggs, Donald Yergeau, Jinjun Cheng, Heather Mulder, Jayanthi Manne, Jesse Jenkins, Michael Dyer, Alberto Pappo and James Downing, all of St. Jude; Carlos Rodriguez-Galindo, of Harvard Medical School, Boston; Troy Lund, of University of Minnesota Medical School, Minneapolis; Elaine Mardis and Richard Wilson, both of Washington University School of Medicine, St. Louis; Maria Mastellaro, of Boldrini Children's Research Hospital, Campinas, Brazil; and Bonald Figueiredo, of Instituto de Pesquisa Pele Pequeno Prıncipe, Curitiba, Brazil.

This work was supported in part by the St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project, including Kay Jewelers, a lead sponsor; a grant (CA21765) from the National Cancer Institute at the National Institutes of Health (NIH); grants (EY014867, EY018599 and CA168875) from NIH; and ALSAC.

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude is working to increase the overall survival rate for childhood cancer to 90 percent in the next decade. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food—because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude at @stjuderesearch.

SOURCE St. Jude Children's Research Hospital

Related Links

http://www.stjude.org